S Siritho1, M Apiwattanakul2, I Nakashima3, T Takahashi4, K Fujihara5, N Prayoonwiwat6. 1. Division of Neurology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand; Bumrungrad International Hospital, Bangkok 10110, Thailand. Electronic address: siritho@yahoo.com. 2. Department of Neurology, Prasat Neurological Institute, Bangkok 10400, Thailand. Electronic address: apiwattanakul.metha@gmail.com. 3. Department of Neurology, Tohoku University School of Medicine, Sendai 980-8574, Japan. Electronic address: nakashima@med.tohoku.ac.jp. 4. Department of Neurology, Tohoku University School of Medicine, Sendai 980-8574, Japan; Department of Neurology, Yonezawa National Hospital, Yonezawa 992-1202, Japan. Electronic address: t-toshiyuki@mta.biglobe.ne.jp. 5. Department of Neurology, Tohoku University School of Medicine, Sendai 980-8574, Japan; Department of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan. Electronic address: fujikazu@med.tohoku.ac.jp. 6. Division of Neurology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. Electronic address: naraporn.pra@mahidol.ac.th.
Abstract
OBJECTIVE: The aim of this study is to investigate the unique features of seronegative neuromyelitis optica spectrum disorders (NMOSD) in Thailand. BACKGROUND: It remains unknown whether seronegative NMOSD patients possess clinical and paraclinical features that are distinct from those with seropositivity. METHODS: In a Thai cohort of idiopathic inflammatory CNS disorders (n=122), 52 patients fulfilled the Wingerchuk 2007 criteria for NMOSD. We determined anti-AQP4 antibody statuses using three different assays (an in-house cell-based assay [CBA], a commercially available CBA and a tissue-based indirect immunofluorescence [IIF] assay). RESULTS: Among the NMOSD patients, the percentage of seropositive cases was 54.5% based on the in-house and commercial CBAs and 30.8% based on the IIF assay. Using the in-house CBA, seronegative NMOSD patients exhibited distinct features compared with seropositive patients, such as a lack of female preponderance (F/M=1.2 vs. 6.0), frequent simultaneous bilateral optic involvement (33.3% vs. 0.04%), a lower annual relapse rate (0.4 ± 0.3 vs. 0.7 ± 0.6), fewer spinal cord lesions (1.0 ± 4.3 vs. 1.4 ± 0.6), and lower CSF cell counts (20 ± 72 vs. 80 ± 285). Use of the commercial CBA yielded essentially similar results, but some of these differences were not significant using IIF. CONCLUSIONS: Sensitive anti-AQP4 antibody assays reveal features of seronegative NMOSD patients that differ from those of seropositive patients from Thailand.
OBJECTIVE: The aim of this study is to investigate the unique features of seronegative neuromyelitis optica spectrum disorders (NMOSD) in Thailand. BACKGROUND: It remains unknown whether seronegative NMOSD patients possess clinical and paraclinical features that are distinct from those with seropositivity. METHODS: In a Thai cohort of idiopathic inflammatory CNS disorders (n=122), 52 patients fulfilled the Wingerchuk 2007 criteria for NMOSD. We determined anti-AQP4 antibody statuses using three different assays (an in-house cell-based assay [CBA], a commercially available CBA and a tissue-based indirect immunofluorescence [IIF] assay). RESULTS: Among the NMOSD patients, the percentage of seropositive cases was 54.5% based on the in-house and commercial CBAs and 30.8% based on the IIF assay. Using the in-house CBA, seronegative NMOSD patients exhibited distinct features compared with seropositive patients, such as a lack of female preponderance (F/M=1.2 vs. 6.0), frequent simultaneous bilateral optic involvement (33.3% vs. 0.04%), a lower annual relapse rate (0.4 ± 0.3 vs. 0.7 ± 0.6), fewer spinal cord lesions (1.0 ± 4.3 vs. 1.4 ± 0.6), and lower CSF cell counts (20 ± 72 vs. 80 ± 285). Use of the commercial CBA yielded essentially similar results, but some of these differences were not significant using IIF. CONCLUSIONS: Sensitive anti-AQP4 antibody assays reveal features of seronegative NMOSD patients that differ from those of seropositive patients from Thailand.
Authors: Stefan M Gold; Anne Willing; Frank Leypoldt; Friedemann Paul; Manuel A Friese Journal: Semin Immunopathol Date: 2018-10-25 Impact factor: 9.623
Authors: Shanthi Viswanathan; Masita Arip; Norhazlin Mustafa; Jasbir S Dhaliwal; Norzainie Rose; Sobri Muda; Santhi Datuk Puvanarajah; Mohammad Hanip Rafia; Mark Cheong Wing Loong Journal: Mult Scler Int Date: 2014-11-17
Authors: Shin Ju Oh; Chun Gyoo Ihm; Tae Won Lee; Jin Sug Kim; Da Rae Kim; Eun Ji Park; Su Woong Jung; Ji-Hoon Lee; Sung Hyuk Heo; Kyung Hwan Jeong Journal: Kidney Res Clin Pract Date: 2017-03-31